Adjuvant management of operated uterine sarcomas: A single institution experience.

PURPOSE: The purpose of this study was to describe the adjuvant management of high grade uterine sarcoma and highlight prognostic factors for overall survival and progression-free survival. MATERIAL AND METHODS: Between 01/2000 and 01/2015, 91 patients undergoing surgery were presented at the multidisciplinary team meeting of our institution. The type of surgery, the anatomopathological features, adjuvant treatments, dates and sites of recurrence were collected. The prognostic value of the various factors was evaluated with the multivariate Cox model. RESULTS: A total of 50 women with uterine sarcoma were identified and lesions included 43 leiomyosarcomas (86%) and seven high grade sarcomas (14%). Eighteen patients received adjuvant pelvic radiotherapy (36%) and six adjuvant systemic therapy (12%). The median follow-up time was 63 months. Thirty-nine patients (78%) had a recurrence: 22 had only metastatic recurrence (58%), two had isolated pelvic recurrence (5%) and 15 had pelvic and metastatic recurrence (38%). Adjuvant radiotherapy was associated with survival without pelvic recurrence in univariate analysis (P=0.005, hazard ratio [HR]=0.15); age greater than 55 years and adjuvant radiotherapy were associated with metastatic free survival in multivariate analysis (P=0.015, HR=2.37, and P=0.013, HR=0.41 respectively) CONCLUSION: According to the results of our series, there is a benefit of radiotherapy after surgery in terms of local control of uterine sarcoma. It is necessary to identify the subgroup of patients who will benefit from an adjuvant radiotherapy in order to provide them with more optimal care.

[Is adaptive intensity-modulated radiotherapy for uterine cervix carcinoma necessary?]. / La radiothérapie (conformationnelle avec modulation d'intensité) adaptative est-elle nécessaire pour les carcinomes du col utérin ?

PURPOSE: To observe on ten patients, the changes of different pelvic structures during a Stade IB2-IIB cervix cancer tomotherapy course delivering 60Gy over 5.5 weeks and evaluate the rationale of adaptive treatments. MATERIALS AND METHODS: Each of the six weekly mega voltage CT-scan (MVCT) exams performed the same day of the week were analyzed. The centro-pelvic CTV volume was contoured as well as the organs at risk (OAR). The dose delivered was recalculated while those to 2%, 50% and 98% of the centro-pelvic CTV as well as to 2 cm(3), 10 cm(3) and 50 cm(3) of the OAR were analyzed. RESULTS: The mean decrease in volume of the centro-pelvic CTV was 13% and non-significant (P>0.2). However four tumors decreased from 21% to 42%. This decrease was centripetal. Likewise, the fraction doses to 2%, 50% and 98% were respectively 2.14±0.08Gy, 2.02±0.14 Gy, 1.8±0.34Gy at week 1 and 2.13±0.1 Gy, 2.06±0.12Gy, 1.88±0.24Gy at week 6 (P>0.2). The doses delivered to 2 cm(3), 10 cm(3) and 50 cm(3) of the different OAR did not change at a significant level (P>0.05) too, except the dose to 50 cm(3) of non-sigmoid bowel moving from 1.69±0.16Gy at week 1 to 1.78±0.14Gy at week 6 (P=0.05). CONCLUSION: As a whole, adaptive therapy does not seem mandatory in this population of stages IB2-IIB cancers. A complementary study on more advanced stages is however necessary.

Cancer-associated hypercalcaemia in squamous-cell malignancies: a survival and prognostic factor analysis.

The aim of this study is to analyse survival and prognostic factors in patients diagnosed with squamous cell carcinoma (SCC) presenting a first episode of cancer-associated hypercalcaemia (CAH). Retrospectively, the authors reviewed data from 220 patients with biopsy proven SCC who presented a first episode of CAH. They were treated in a single centre between 1995 and 2007. The survival analyses were done using the Kaplan-Meier method and Cox analysis. The primary endpoint was the overall survival from the date of hypercalcaemia episode. Median age was 55 years. Median survival was 64 days (1-197). Three independent prognostic factors were identified: brain metastasis (hazard ratio (HR)=2.58 CI (1.03-6.45)), corrected calcaemia>3 mmol/l (HR=1.45 CI (1.05-2.01)) and hypoalbuminaemia (HR=1.48 CI (1.07-2.04)). Using these factors, the authors performed a bedside prognostic score. In conclusion, median survival in patients diagnosed with SCC and CAH is extremely poor. The bedside prognostic score that the authors developed can help to anticipate patients' prognosis and adapt the treatment. This score needs to be validated on an independent cohort.